Top Line: Data is mounting for dose-escalation of twice-daily (BID) definitive radiation for small cell lung cancer (SCLC).
The Study: Recall the last few years have brought us phase II data with 60 Gy over 40 BID treatments and randomized phase III data with a simultaneous integrated boost (SIB) to 54 Gy over standard 30 BID treatments, each achieving overall survival times that blow the standard 45 Gy in 30 BID treatments out of the water. In this hefty real-world Chinese retrospective review, investigators compared three familiar contenders across 353 patients treated between 2010-2024: 45 Gy BID, 60–70 Gy once-daily, and the newer 54 Gy SIB-BID all delivered via VMAT. Importantly all patients received IMRT and at least 4 cycles of concurrent chemo. After adjusting for measurable variables, 54 Gy BID again produced impressive overall survival outcomes at a median of 64 months versus 43 with 45 Gy BID and 38 with once-daily treatment. There was a corresponding divergence in median progression-free survival at 30 months versus 15 versus 13.5 months, respectively. Notably, the gains appeared driven by improved local control rather than distant metastasis. And, again, there appeared to be no real difference in rates of grade 3–4 esophagitis (20–23%) and pneumonitis (2–3%). We’re still lacking detail on the SIB planning goals but presumably you cover as much gross disease as possible with 54 Gy while respecting longstanding 30-fraction BID constraints.
TBL: Recognizing this data is ideally robustly reproduced in Western populations, the strategy seems like one many rad oncs can adopt with reasonable expectations to improve cancer control in a safe and feasible way. | Yu, Pract Radiat Oncol 2026
The Study: Recall the last few years have brought us phase II data with 60 Gy over 40 BID treatments and randomized phase III data with a simultaneous integrated boost (SIB) to 54 Gy over standard 30 BID treatments, each achieving overall survival times that blow the standard 45 Gy in 30 BID treatments out of the water. In this hefty real-world Chinese retrospective review, investigators compared three familiar contenders across 353 patients treated between 2010-2024: 45 Gy BID, 60–70 Gy once-daily, and the newer 54 Gy SIB-BID all delivered via VMAT. Importantly all patients received IMRT and at least 4 cycles of concurrent chemo. After adjusting for measurable variables, 54 Gy BID again produced impressive overall survival outcomes at a median of 64 months versus 43 with 45 Gy BID and 38 with once-daily treatment. There was a corresponding divergence in median progression-free survival at 30 months versus 15 versus 13.5 months, respectively. Notably, the gains appeared driven by improved local control rather than distant metastasis. And, again, there appeared to be no real difference in rates of grade 3–4 esophagitis (20–23%) and pneumonitis (2–3%). We’re still lacking detail on the SIB planning goals but presumably you cover as much gross disease as possible with 54 Gy while respecting longstanding 30-fraction BID constraints.
TBL: Recognizing this data is ideally robustly reproduced in Western populations, the strategy seems like one many rad oncs can adopt with reasonable expectations to improve cancer control in a safe and feasible way. | Yu, Pract Radiat Oncol 2026